Recent Advances in the Treatment of Advanced HER2+ Breast Cancer: SABCS 2024 - Episode 4

Emerging Data and Treatment Considerations in HER2 Ultralow Breast Cancer

, , , ,

Panelists discuss how emerging data on HER2-ultralow breast cancer is informing treatment decisions, particularly regarding the potential role of trastuzumab deruxtecan, while acknowledging the need for careful patient selection and consideration of traditional treatment sequences.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Precision Medicine in Breast Cancer: Evolving Paradigms in HER2 Testing and Clinical Implications
    EP. 2: ADCs in HER2-Low Breast Cancer: Insights From DESTINY-Breast04, TROPiCS-02, and TROPION-Breast02
    EP. 3: T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights
    Now Viewing
    EP. 4: Emerging Data and Treatment Considerations in HER2 Ultralow Breast Cancer
    EP. 5: Patient-Reported Outcomes and Quality of Life Data With T-DXd in HER2-(Ultra) Low mBC
    EP. 6: Proactive AE Management and Prophylactic Strategies With TADCs in Breast Cancer
    EP. 7: Evolving Paradigms in HER2+ Advanced Breast Cancer With Brain Metastases
    EP. 8: Precision in CNS Targeting: Optimizing Management of Brain Metastases in HER2+ Breast Cancer
    EP. 9: Insights From DESTINY-Breast12 Evaluating T-DXd in HER2+ Breast Cancer and Active and Stable Brain Metastases
    EP. 10: Novel and Emerging Strategies for HER2+ Breast Cancer With Brain Metastases
    EP. 11: Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer
    EP. 12: SABCS Highlights and Future Directions in the Treatment of Breast Cancer

    Video content above is prompted by the following:

    • Briefly discuss how you approach treatment for patients with HER2-ultralow metastatic breast cancer.
    • How does your treatment strategy for patients with HER2-ultralow breast cancer differ from your approach in patients with HER2-positive and HER2-low status?
    • Are you currently implementing the DESTINY-Breast06 regimen in your clinical practice for patients with HER2 ultra-low breast cancer? If so, please elaborate on patient selection and sequencing.
    x